Liquidia Shares Jump 17% to $50.50 as Q1 Revenue Surges to $132.9 Million
Updated
Updated · MarketWatch · May 11
Liquidia Shares Jump 17% to $50.50 as Q1 Revenue Surges to $132.9 Million
5 articles · Updated · MarketWatch · May 11
Liquidia stock rose 17% Monday to $49.56 after touching a record $50.50 as first-quarter results topped Wall Street expectations.
$132.9 million in revenue, up from $3.1 million a year earlier and above the $119.4 million consensus, was driven mainly by $129.9 million in Yutrepia sales.
$52.9 million in profit, or 52 cents a share, beat analysts' 41-cent estimate and improved from $38.4 million, or 45 cents a share, a year earlier.
Yutrepia has become the company's key growth engine since Liquidia began U.S. shipments in June 2025, shortly after the FDA approved the pulmonary hypertension treatment on May 23, 2025.
With blockbuster sales, can Liquidia’s Yutrepia survive the high-stakes patent war against its biggest rival?
After a record launch, is Liquidia’s next drug L606 poised to conquer an even larger market?